This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 15, 2014
- BioPharm International-11-15-2014
- Volume 2104 eBook
- Issue 4
Best Practices for Quality Control and Implementation of Single-Use Systems By Jerold Martin
Author(s)Jerold M. Martin
New publications from BPSA and PDA highlight best practices for particulate control, quality agreements, and implementation strategies.
Advertisement
New publications from BPSA and PDA highlight best practices for particulate control, quality agreements, and implementation strategies.
from BioPharm International’s 2014 Secure Single-Use Systems eBook.
Articles in this issue
almost 12 years ago
Innovations in Single-Use Bioprocessing Componentsalmost 12 years ago
Budgets Increase to Support Single-Use Bioprocessingalmost 12 years ago
Optimizing Resin Performance with Disposable Chromatography Solutionsalmost 12 years ago
Security of the Single-Use Supply Chain: Is Dual Sourcing the Answer?almost 12 years ago
Trends in Single-Use BioreactorsAdvertisement
Related to this article
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
5